STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADPT
  4. [144] Adaptive Biotechnologies Corp SEC Filing

Adaptive Biotechnologies (NASDAQ: ADPT) director plans to resell 30,664 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Adaptive Biotechnologies Corporation (ADPT) director Robert M. Hershberg filed a notice of proposed resale under Rule 144. The filing covers up to 30,664 shares of common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $748,303.36. The calculation references 159,595,842 shares outstanding as of August 18, 2026, and includes shares from stock option exercises and restricted stock.

Positive

  • None.

Negative

  • None.
Shares proposed for resale 30,664 shares Common stock covered by the Rule 144 notice
Aggregate market value $748,303.36 Value of 30,664 shares proposed for resale
Shares outstanding 159,595,842 shares ADPT common shares outstanding as of August 18, 2026
Stock option shares 15,000 shares Shares underlying stock option exercise dated August 18, 2026
Restricted stock shares 15,664 shares Restricted stock dated March 4, 2025 included in resale amount
Rule 144 regulatory
"filed a notice of proposed resale under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock financial
"Common | 03/04/2025 | Restricted Stock | Issuer"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Stock Option Exercise financial
"Common | 08/18/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
aggregate market value financial
"30664 | 748303.36 | 159595842 | 08/18/2026"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing mean for Adaptive Biotechnologies (ADPT)?
The filing indicates director Robert M. Hershberg plans a potential resale of up to 30,664 shares of ADPT common stock under Rule 144. It is a notice of proposed sales and does not itself execute transactions.

How many Adaptive Biotechnologies (ADPT) shares are covered by this Form 144?
The Form 144 covers up to 30,664 shares of ADPT common stock. These shares come from a 15,000-share stock option exercise and 15,664 restricted shares, together forming the maximum amount proposed for resale.

What is the aggregate market value of the ADPT shares in this Form 144?
The proposed resale covers an aggregate market value of $748,303.36 of ADPT common stock. This value is based on the 30,664 shares covered by the notice and reflects pricing used solely for this Rule 144 filing.

How many Adaptive Biotechnologies (ADPT) shares were outstanding for this Form 144?
The filing references 159,595,842 shares of ADPT common stock outstanding as of August 18, 2026. This figure is used in the Form 144 disclosure as context for the proposed resale amount.

What types of ADPT equity are involved in Robert Hershberg’s Form 144?
The notice includes shares from a stock option exercise of 15,000 shares dated August 18, 2026, and 15,664 restricted stock shares dated March 4, 2025. Together they comprise the 30,664 shares proposed for resale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR